Post-menopausal women with high levels of hormones such as estrogen or testosterone are known to have a higher risk of breast cancer. New research published in BioMed Central's open access journal Breast Cancer Research looked at eight different sex and growth hormones and found that the risk of breast cancer increased with the number of elevated hormones - each additional elevated hormone level increased risk by 16%.
Researchers from the Brigham and Women's Hospital and Harvard Medical School used blood samples collected from nurses up to nine years before health information, including their breast cancer status, was recorded. Post-menopausal women who were diagnosed with breast cancer were matched to two controls of a similar age.
The highest levels of circulating estrogens (estrone and estrogen), prolactin, and androgens (testosterone, androstenedione, DHEA, or DHEA-sulfate) were individually associated with between 50 and 200% increase in breast cancer risk. The number of different hormones elevated above normal further increased risk, so that women with one elevated hormone had an increased risk of 10% (compared to normal levels), but the risk for women with five or six elevated hormone levels was doubled, and that for women with seven or eight was tripled. All these risks were slightly higher for women with ER positive disease.
Dr Shelley Tworoger, from Brigham and Women's Hospital, commented that, "Elevated estrogens had the biggest effect on risk, especially for ER positive cancer. However, androgens, and prolactin also contribute to increasing risk of breast cancer. These hormones are known to stimulate the growth of breast cancer cells in the lab and, while androgens can be converted to estrogen in the body, these hormones have also been found to stimulate cancer cell growth in the absence of ER. Our results suggest that models used to assess breast cancer risk could be improved by taking into account multiple sex hormone and growth hormone levels."
Notes to Editors
1. The combined influence of multiple sex and growth hormones on risk of postmenopausal breast cancer: a nested case-control study
Shelley S Tworoger, Bernard A Rosner, Walter C Willett and Susan E Hankinson
Breast Cancer Research (in press)
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at press@biomedcentral.com on the day of publication.
2. Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, commentaries and reports. Research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition, the journal publishes clinical studies with a biological basis, including Phase I and Phase II trials.
3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
Journal
Breast Cancer Research